Alan Ho
Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Centre, 1275 York Avenue, New York, NY 10065. · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alan Ho as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06891560 · A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaMemorial Sloan Kettering Cancer Center · recruiting · Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT06007924 · A Study of Avutometinib and Defactinib in People With Thyroid CancerMemorial Sloan Kettering Cancer Center · recruiting · Thyroid Cancer · principal investigator
- Ph2NCT04209660 · Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer Center · active not recruiting · Adenoid Cystic Carcinoma, Salivary Gland Cancer · principal investigator
- Early Ph1NCT03215095 · RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid CancersMemorial Sloan Kettering Cancer Center · active not recruiting · Thyroid Cancer · principal investigator
- Ph2NCT03172624 · Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerMemorial Sloan Kettering Cancer Center · completed · Salivary Gland Cancer · principal investigator
- Ph2NCT02780310 · Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaMemorial Sloan Kettering Cancer Center · active not recruiting · Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT02749903 · Enzalutamide for Patients With Androgen Receptor Positive Salivary CancersAlliance for Clinical Trials in Oncology · active not recruiting · Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma · study chair
- Ph2NCT02098538 · Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaMemorial Sloan Kettering Cancer Center · completed · Adenoid Cystic Carcinoma · principal investigator
- Ph3NCT01843062 · Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid CancerAstraZeneca · terminated · Differentiated Thyroid Cancer · principal investigator
- Ph2NCT01604772 · Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaNational Cancer Institute (NCI) · completed · Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma · principal investigator
- Ph2NCT01183065 · Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)Memorial Sloan Kettering Cancer Center · completed · Head and Neck Cancer · principal investigator
- N/ANCT00970359 · Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244Memorial Sloan Kettering Cancer Center · completed · Thyroid Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 50 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland CancerR01FD008542 · FDA · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2026 · $2,583,632 awarded in 2026Same name and institution; not confirmed by an ID
- Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancersR01FD008181 · FDA · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2024 to 2026 · $216,447 awarded in 2026Same name and institution; not confirmed by an ID
- Improving efficacy of radioiodine treatment of thyroid cancerR01CA249663 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2025 · $471,416 awarded in 2025Same name and institution; not confirmed by an ID
- Identifying and targeting neoantigens in aggressive salivary carcinomasR01DE027738 · NIDCR · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2018 to 2022 · $455,430 awarded in 2022Same name and institution; not confirmed by an ID
- Targeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid CancerR01CA184724 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2015 to 2017 · $620,308 awarded in 2017Same name and institution; not confirmed by an ID
- Targeting the Oncogenic Transcription Factor c-myb in Adenoid Cystic CarcinomasR01CA166978 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2012 to 2013 · $328,386 awarded in 2013Grant number is on one of their registry trials
- Immunization Against Melanoma Differentiation AntigensR01CA056821 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1992 to 2012 · $305,986 awarded in 2012Same name and institution; not confirmed by an ID
- Genetic Approaches to Immune AdjuvantsP01CA059350 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1997 to 2010 · $344,468 awarded in 2010Same name and institution; not confirmed by an ID
- Administrative CoreP01CA033049 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1985 to 2009 · $452,135 awarded in 2009Same name and institution; not confirmed by an ID
- Immunology Research TrainingT32CA009149 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1997 to 2005 · $188,052 awarded in 2005Same name and institution; not confirmed by an ID
- CLINICAL STUDIES/TRIALSP01CA047179 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2000 to 2003 · $230,631 awarded in 2003Same name and institution; not confirmed by an ID
- IMMUNOLOGYP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1998 to 2002 · $157,506 awarded in 2002Same name and institution; not confirmed by an ID
- CLINICAL TRIALS OF MONOCLONAL ANTIBODIES-IMMUNON01CM097609 · NCI · MEMORIAL HOSPITAL FOR CANCER & ALLIED DI · fiscal years 1989 to 1994 · $200,000 awarded in 1994Same name and institution; not confirmed by an ID
- PHASE I TRIAL (FAB1/2 FRAGMENTS OF R24 MELANOMAN01CM047665 · NCI · MEMORIAL HOSPITAL FOR CANCER & ALLIED DI · fiscal years 1985 to 1992Same name and institution; not confirmed by an ID
- SPECIFICITY OF MONOCLONAL ANTIBODIES TO HUMAN CANCERR01CA034079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1985 · $138,803 awarded in 1985Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT01604772
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT01604772
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:26 UTC. The ranking covers the 200 most relevant of 305 PubMed records, and a shared surname and initials can bring in a namesake. All 305 on PubMed
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol · 19982,305 citationsRCR 51.3
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.Ophthalmology · 20122,057 citationsRCR 76.1
- Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.Ophthalmology · 2014704 citationsRCR 30.9
- Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.N Engl J Med · 2010692 citationsRCR 17.4
- Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.N Engl J Med · 2013643 citationsRCR 19.6
- Interim results from the international trial of Second Sight's visual prosthesis.Ophthalmology · 2012480 citationsRCR 16.5
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.J Clin Oncol · 2021367 citationsRCR 19.3
- Microglial activation correlates with severity in Huntington disease: a clinical and PET study.Neurology · 2006356 citationsRCR 8.3
- Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys · 2004332 citationsRCR 8.4
- Treatment of periodontal disease in diabetics reduces glycated hemoglobin.J Periodontol · 1997321 citationsRCR 12.9